ANDA > Nova Content
Written by:Nima Zargari, Ph.D. & Joseph Mallon, Ph.D.
On April 26, 2023, the European Commission proposed a pharmaceutical law... Read More »
SANOFI-AVENTIS DEUTSCHLAND GMBH V. MYLAN PHARMACEUTICALS INC.
Before Reyna, Mayer, and Cunningham. Appeal from Patent Trial and Appeal... Read More »
Written by: Jeremy Anapol
UNITED CANNABIS CORPORATION V. PURE HEMP COLLECTIVE INC.
Before Lourie, Cunningham, and Stark... Read More »
Written by: Matthew S. Whitehead & Douglas B. Wentzel
UCB, INC. v. ACTAVIS LABORATORIES UT, INC.
Before Moore, Chen, and... Read More »
Written by: Ari Feinstein & Agnes Juang, Ph.D.
On March 29, 2023, the Solicitor General of the United States asked the Supreme... Read More »
Written by: Brandon D. Hupka & Hans L. Mayer
REGENTS OF THE UNIVERSITY OF MINNESOTA V. GILEAD SCIENCES, INC.
Before... Read More »
Written by: Tyler S. Cox & Kendall Loebbaka
JAZZ PHARMACEUTICALS, INC. v. AVADEL CNS PHARMACEUTICALS, LLC
Before Lourie... Read More »
Written by: Mark Rubinshtein, Ph.D.
Biopharmaceutical New Technologies (BioNTech), the global immunotherapy company based in... Read More »
Written by: Kendall Loebbaka & Cesar A. Estrada
GENENTECH, INC. V. SANDOZ INC.
Before Newman, Lourie, and Prost. Appeal... Read More »
In late August, we published our third annual ANDA Litigation Intelligence Report. We evaluated the stakeholders for Hatch-Waxman cases filed... Read More »
In late August, we published our third annual ANDA Litigation Intelligence Report, covering important statistics and evaluating all stakeholders in ... Read More »
MYLAN PHARMACEUTICALS INC. v. MERCK SHARP & DOHME CORP.
Before Lourie, Reyna and Stoll. Appeal from the Patent Trial and Appeal... Read More »
Last August, we published our third annual ANDA Litigation Intelligence Report. The report covered the ANDA litigation landscape and focused on... Read More »
Last month, we released our third annual ANDA Litigation Intelligence Report evaluating all stakeholders in ANDA/Hatch-Waxman cases filed over the... Read More »
In late August we released our third annual ANDA Litigation Intelligence Report. The report covered the ANDA litigation landscape by providing... Read More »
The Federal Circuit has affirmed that Eagle Pharmaceuticals, Inc. did not infringe Par Pharmaceutical, Inc. patents, easing... Read More »
Two days ago, the companies that joined forces in order to develop the first Covid vaccine that got approval for emergency use by FDA... Read More »
PAR PHARMACEUTICAL, INC. V. EAGLE PHARMACETICALS, INC.
Before Moore, Prost, and Hughes. Appeal from the United States District Court for... Read More »
This morning we released our third annual ANDA Litigation Intelligence Report. The report covers high-level statistics related to Hatch-Waxman... Read More »
The FDA evaluates the generic versions of a drug and approves them only if studies show that it is bioequivalent with the... Read More »